2007/042 NICE responds to judicial review outcome

Commenting on today’s ruling, NICE Chief Executive, Andrew Dillon said: “The legal challenge to our recommendation that drugs for Alzheimer’s disease should only be prescribed to those in the moderate stage of the disease has failed. We were challenged on six grounds, and the court found in our favour on five of them. This ruling strengthens NICE by endorsing our approach to evaluating drugs."